Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Post-Market Drug Surveillance Research Methods Are Focus Of Reagan-Udall Program

This article was originally published in The Pink Sheet Daily

Executive Summary

The Reagan-Udall Foundation has established an organizing committee to help inform the design and structure of what its Innovation in Medical Evidence Development and Surveillance program’s post-market research methods should look like and develop the IMEDS charter.


Related Content

Reagan-Udall, Pfizer Testing Ways To Tap Sentinel Network Without FDA
Reagan-Udall, Still Waiting For FDA Funding, Studies Drug Toxicity Pathways





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts